Get started
Author

MATTHEW KEITH

Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
2024 · Marc E. Rothenberg, Evan S. Dellon, et al. · New England Journal of Medicine · 114
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma
2021 · Monica Kraft, Guy Brusselle, et al. · European Respiratory Journal · 76
PDF
610 Efficacy and Safety of Benralizumab in Adults and Adolescents With Eosinophilic Esophagitis: Results From the 24-week Double-blind Period of the Phase 3 Messina Trial
2023 · Marc E. Rothenberg, Evan S. Dellon, et al. · Gastroenterology · 13
PDF
Enabling Reductions in Maintenance ICS/LABA Therapy Using as Needed Anti-Inflammatory Reliever for Patients with Severe Eosinophilic Asthma Controlled with Benralizumab: SHAMAL Phase IV Clinical Study
2020 · D.J. Jackson, B.D. Kent, et al. · 4
The Phase 3 Natron Study Evaluating Benralizumab in Patients with Hypereosinophilic Syndrome: Study Design and Patient Characteristics
2023 · Praveen Akuthota, Amy D Klion, et al. · Blood · 2
Patient Clinical Characteristics and Biomarkers Associated with Underlying Exacerbation Risk in Asthma
2020 · M. Kraft, G. Brusselle, et al. · 1
Efficacy of Albuterol-budesonide vs Albuterol in Mild Asthma on Disease Control Over Time
2026 · Kevin Murphy, Alberto Papi, et al. · Journal of Allergy and Clinical Immunology
Albuterol-Budesonide Treatment in Acute Airway Obstruction Provides Enhanced Lung Function Improvement for Patients With Well-Controlled and Uncontrolled Mild Asthma
2026 · Autumn Burnette, Reynold Panettieri, et al. · Journal of Allergy and Clinical Immunology
Efficacy Of As-needed Albuterol‒Budesonide Versus Albuterol In Participants With Mild Asthma Not On Maintenance Therapy: BATURA Post-hoc Analysis
2026 · Monica Kraft, Reynold Panettieri, et al. · Journal of Allergy and Clinical Immunology
Use of as-needed Albuterol–budesonide Is Associated with a Higher Probability of Symptom-free Nights Than as-needed Albuterol in Moderate-to-Severe Asthma
2026 · Bradley Chipps, Richard Beasley, et al. · Journal of Allergy and Clinical Immunology
PDF
Albuterol-budesonide Treatment in Acute Airway Obstruction: Onset and Duration of Lung Function and Symptom Improvement
2025 · R. Panettieri, P. Akuthota, et al. · Annals of Allergy Asthma & Immunology
Albuterol–budesonide Reduces Exacerbations in Uncontrolled Mild Asthma With or Without Exacerbation History-based Risk
2025 · B. Chipps, R. Beasley, et al. · Annals of Allergy Asthma & Immunology
Use of As-needed Albuterol–budesonide Versus Albuterol Before and After a Severe Exacerbation: Batura Post-hoc Analysis
2025 · N. Skolnik, J. Cardet, et al. · Annals of Allergy Asthma & Immunology
As-needed Albuterol-budesonide Vs As-needed Albuterol Decreases Severe Exacerbation Risk and Improves Asthma Control at 16 Weeks in Mild Asthma: Batura Post-hoc Analyses
2025 · REYNOLD A PANETTIERI, BRADLEY E CHIPPS, et al. · CHEST Journal
Asthma Control in Participants With Mild Asthma Enrolled in the Batura Clinical Trial: Impairment and Risk Profiles at Randomization
2025 · MIGUEL J LANZ, BRADLEY E CHIPPS, et al. · CHEST Journal
Albuterol-Budesonide Treatment in Acute Airway Obstruction: Patient Selection for the ALTA Study
2025 · P. Akuthota, R.A. Panettieri, et al. · American Journal of Respiratory and Critical Care Medicine
Works count: 16
Citation count: 210
H-index: 4
I10-index: 3
Year
Topic
Type